Alnylam Pharma Files 2025 Proxy: Executive Equity Awards Detailed
Ticker: ALNY · Form: DEF 14A · Filed: Mar 24, 2025 · CIK: 1178670
| Field | Detail |
|---|---|
| Company | Alnylam Pharmaceuticals, Inc. (ALNY) |
| Form Type | DEF 14A |
| Filed Date | Mar 24, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, equity-awards
Related Tickers: ALNY
TL;DR
Alnylam's proxy filing shows exec equity awards for 2020-2024. See how much top brass got.
AI Summary
Alnylam Pharmaceuticals, Inc. filed its DEF 14A on March 24, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and equity awards granted to its "principal executive officers" (PEO) for the years 2020 through 2024. It includes information on the year-end value of outstanding and unvested equity awards for these officers.
Why It Matters
This filing provides transparency into how Alnylam Pharmaceuticals compensates its top executives, offering insights into the company's incentive structures and potential alignment with shareholder interests.
Risk Assessment
Risk Level: low — This is a routine proxy filing detailing executive compensation and equity awards, which is standard for public companies.
Key Numbers
- 2020-2024 — Reporting Period for Equity Awards (Covers executive equity awards granted over five fiscal years.)
Key Players & Entities
- ALNYLAM PHARMACEUTICALS, INC. (company) — Filer of the DEF 14A
- 0001178670-25-000040 (document_id) — Accession Number for the filing
- 20250324 (date) — Filing date
- 20250508 (date) — Conformed period of report
- 2024-12-31 (date) — Fiscal year end
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide information regarding the solicitation of proxies for the company's annual meeting of stockholders, including details on executive compensation and corporate governance.
Which fiscal years are covered by the executive compensation data in this filing?
The filing covers executive compensation data for the fiscal years 2020 through 2024.
What specific type of compensation is detailed for the principal executive officers?
The filing details equity awards granted to principal executive officers, including the year-end value of outstanding and unvested equity awards.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on March 24, 2025.
What is the company's fiscal year end?
Alnylam Pharmaceuticals, Inc.'s fiscal year ends on December 31st.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on March 24, 2025 regarding ALNYLAM PHARMACEUTICALS, INC. (ALNY).